Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
914.20 DKK | +2.66% | +3.28% | +30.96% |
11:36am | Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production | RE |
10:40am | NOVO NORDISK : Deutsche Bank keeps its Buy rating | ZD |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 122B | 127B | 141B | 177B | 232B | |||||
Total Revenues | 122B | 127B | 141B | 177B | 232B | |||||
Cost of Goods Sold, Total | 19.56B | 20.93B | 23.66B | 28.45B | 35.76B | |||||
Gross Profit | 102B | 106B | 117B | 149B | 196B | |||||
Selling General & Admin Expenses, Total | 35.83B | 36.89B | 41.06B | 50.68B | 61.6B | |||||
R&D Expenses | 13.77B | 15.11B | 17.2B | 23.29B | 31.03B | |||||
Other Operating Expenses | -600M | -460M | -456M | -1.08B | -119M | |||||
Other Operating Expenses, Total | 49B | 51.54B | 57.8B | 72.89B | 92.51B | |||||
Operating Income | 53.46B | 54.48B | 59.34B | 75.62B | 104B | |||||
Interest Expense, Total | -220M | -390M | -289M | -378M | -542M | |||||
Interest And Investment Income | 65M | 337M | 231M | 239M | 1.07B | |||||
Net Interest Expenses | -155M | -53M | -58M | -139M | 527M | |||||
Income (Loss) On Equity Invest. | -137M | 149M | -24M | -189M | 81M | |||||
Currency Exchange Gains (Loss) | -3.21B | -747M | 344M | -4.65B | 1.65B | |||||
Other Non Operating Income (Expenses) | -281M | -150M | -122M | -181M | -197M | |||||
EBT, Excl. Unusual Items | 49.68B | 53.68B | 59.48B | 70.46B | 106B | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | - | - | -124M | -51M | - | |||||
Gain (Loss) On Sale Of Investments | -145M | -195M | 296M | -587M | 37M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | -979M | -350M | -573M | -760M | -1.41B | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 48.55B | 53.13B | 59.08B | 69.06B | 105B | |||||
Income Tax Expense | 9.6B | 10.99B | 11.32B | 13.54B | 20.99B | |||||
Earnings From Continuing Operations | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | |||||
Net Income to Company | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | |||||
Net Income - (IS) | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | |||||
Net Income to Common Incl Extra Items | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | |||||
Net Income to Common Excl. Extra Items | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 8.2 | 9.03 | 10.4 | 12.26 | 18.67 | |||||
Basic EPS - Continuing Operations | 8.2 | 9.03 | 10.4 | 12.26 | 18.67 | |||||
Basic Weighted Average Shares Outstanding | 4.75B | 4.67B | 4.59B | 4.53B | 4.48B | |||||
Net EPS - Diluted | 8.19 | 9 | 10.37 | 12.22 | 18.62 | |||||
Diluted EPS - Continuing Operations | 8.19 | 9 | 10.37 | 12.22 | 18.62 | |||||
Diluted Weighted Average Shares Outstanding | 4.76B | 4.68B | 4.61B | 4.54B | 4.49B | |||||
Normalized Basic EPS | 6.54 | 7.19 | 8.09 | 9.72 | 14.79 | |||||
Normalized Diluted EPS | 6.53 | 7.17 | 8.07 | 9.69 | 14.75 | |||||
Dividend Per Share | 4.18 | 4.55 | 5.2 | 6.2 | 9.4 | |||||
Payout Ratio | 49.83 | 47.75 | 45.06 | 45.57 | 37.96 | |||||
American Depositary Receipts Ratio (ADR) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |||||
Supplemental Items | ||||||||||
EBITDA | 57.07B | 58.79B | 63.55B | 80.93B | 110B | |||||
EBITA | 53.95B | 55.57B | 60.21B | 77.02B | 106B | |||||
EBIT | 53.46B | 54.48B | 59.34B | 75.62B | 104B | |||||
EBITDAR | 57.44B | 59.1B | 64.86B | 82.42B | 112B | |||||
Effective Tax Rate - (Ratio) | 19.78 | 20.69 | 19.17 | 19.6 | 20.05 | |||||
Total Current Taxes | 11.08B | 10.99B | 13.27B | 18.17B | 25B | |||||
Total Deferred Taxes | -1.48B | -2M | -1.94B | -4.63B | -4.01B | |||||
Normalized Net Income | 31.05B | 33.55B | 37.18B | 44.04B | 66.28B | |||||
Interest on Long-Term Debt | 108M | 97M | - | - | - | |||||
Non-Cash Pension Expense | 151M | 138M | 139M | 185M | 126M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 31.82B | 32.93B | 37.01B | 46.22B | 56.74B | |||||
General and Administrative Expenses | 4.01B | 3.96B | 4.05B | 4.47B | 4.86B | |||||
Research And Development Expense From Footnotes | 14.22B | 15.46B | 17.77B | 24.05B | 32.44B | |||||
Net Rental Expense, Total | 377M | 312M | 1.3B | 1.49B | 1.83B | |||||
Imputed Operating Lease Interest Expense | 266M | 131M | 163M | 172M | 301M | |||||
Imputed Operating Lease Depreciation | 111M | 181M | 1.14B | 1.32B | 1.53B | |||||
Stock-Based Comp., Other (Total) | 363M | 823M | 1.04B | 1.54B | 2.15B | |||||
Total Stock-Based Compensation | 363M | 823M | 1.04B | 1.54B | 2.15B |